These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

924 related articles for article (PubMed ID: 33548931)

  • 1. Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era.
    MacDougall K; Spyropoulos AC
    Semin Respir Crit Care Med; 2021 Apr; 42(2):308-315. PubMed ID: 33548931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
    Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
    Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
    Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
    Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New paradigms in venous thromboprophylaxis of medically ill patients.
    Spyropoulos AC; Raskob GE
    Thromb Haemost; 2017 Aug; 117(9):1662-1670. PubMed ID: 28640324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients.
    MacDougall K; Spyropoulos AC
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32252423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective.
    Spyropoulos AC; Ageno W; Cohen AT; Gibson CM; Goldhaber SZ; Raskob G
    Thromb Haemost; 2020 Jun; 120(6):924-936. PubMed ID: 32492724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients.
    Gibson CM; Nafee T; Yee MK; Chi G; Korjian S; Daaboul Y; AlKhalfan F; Kerneis M; Goldhaber SZ; Hull R; Hernandez AF; Cohen AT; Harrington RA
    Am Heart J; 2018 Apr; 198():84-90. PubMed ID: 29653652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
    J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
    Nafee T; Gibson CM; Yee MK; Alkhalfan F; Chi G; Travis R; Mir M; Kalayci A; Jafarizade M; Ganti A; Kazmi SH; Ghaffarpasand E; Pitliya A; Datta S; Sharfaei S; Alihashemi M; Elsaiey A; Qamar I; Jahansouz M; Talib U; Kahe F; Habibi S; Abdelwahed M; Tariq F; Kaur M; Younes A; Walia SS; Singh A; Dildar SM; Afzal MK; Kerneis M
    Expert Rev Cardiovasc Ther; 2018 Nov; 16(11):845-855. PubMed ID: 30296387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.
    Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos A; Tapson V
    J Thromb Thrombolysis; 2011 May; 31(4):407-16. PubMed ID: 21359646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
    Escolar G; Díaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 Aug; 53(8):423-434. PubMed ID: 29119147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups.
    Jamil A; Jamil U; Singh K; Khan F; Chi G
    Crit Pathw Cardiol; 2021 Mar; 20(1):16-24. PubMed ID: 32657973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended Thromboprophylaxis for Medical Patients.
    Dalen JE; Stein PD; Plitt JL; Jaswal N; Alpert JS
    Am J Med; 2020 Jan; 133(1):9-11. PubMed ID: 31247174
    [No Abstract]   [Full Text] [Related]  

  • 14. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
    Gibson CM; Halaby R; Korjian S; Daaboul Y; Arbetter DF; Yee MK; Goldhaber SZ; Hull R; Hernandez AF; Lu SP; Bandman O; Leeds JM; Gold A; Harrington RA; Cohen AT;
    Am Heart J; 2017 Mar; 185():93-100. PubMed ID: 28267480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization.
    Engelen MM; Vandenbriele C; Balthazar T; Claeys E; Gunst J; Guler I; Jacquemin M; Janssens S; Lorent N; Liesenborghs L; Peerlinck K; Pieters G; Rex S; Sinonquel P; Van der Linden L; Van Laer C; Vos R; Wauters J; Wilmer A; Verhamme P; Vanassche T
    Semin Thromb Hemost; 2021 Jun; 47(4):362-371. PubMed ID: 33893631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Betrixaban: A Novel Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients.
    Lee K; Cham S; Lam S
    Cardiol Rev; 2018; 26(6):331-338. PubMed ID: 30067518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?
    Al Yami MS; Alfayez OM; Kurdi SM; Alsheikh R
    J Thromb Thrombolysis; 2017 Jul; 44(1):1-8. PubMed ID: 28197755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.
    Laskier V; Guy H; Fisher M; Neuman WR; Bucior I; Cohen AT; Ren S
    J Med Econ; 2019 Oct; 22(10):1063-1072. PubMed ID: 31314619
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of extended thromboprophylaxis for medically ill patients. A meta-analysis of randomised controlled trials.
    Dentali F; Mumoli N; Prisco D; Fontanella A; Di Minno MN
    Thromb Haemost; 2017 Feb; 117(3):606-617. PubMed ID: 28078350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients.
    Spyropoulos AC
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):506-514. PubMed ID: 36485109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.